LACK OF A PHARMACOKINETIC INTERACTION BETWEEN DIMEBON (LATREPIRDINE) AND DIGOXIN IN HEALTHY SUBJECTS.

被引：0
|
作者：
Qiu, R. [1 ]
Plowchalk, D. [1 ]
Byon, W. [1 ]
Terra, S. [1 ]
Corrigan, B. [1 ]
Mordenti, J. [2 ]
Fang, J. [1 ]
Fullerton, T. [1 ]
机构：
[1] Pfizer Inc, Groton, CT 06340 USA
[2] Medivation Inc, San Francisco, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 87卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S91 / S91
页数：1
相关论文
共 50 条
  • [1] LACK OF A PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION BETWEEN DIMEBON (LATREPIRDINE) AND WARFARIN IN HEALTHY SUBJECTS.
    Plowchalk, D. R.
    Qiu, R.
    Terra, S. G.
    Corrigan, B.
    Fang, J.
    Fullerton, T.
    Liu, J.
    Byon, W.
    Mordenti, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S57 - S57
  • [2] No pharmacokinetic interaction between saxagliptin and digoxin in healthy subjects.
    Boulton, D. W.
    Li, L.
    Patel, C. G.
    Komoroski, B. J.
    Whigan, D.
    Frevert, E. U.
    Kornhauser, D. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S93 - S93
  • [3] LACK OF A PHARMACOKINETIC INTERACTION BETWEEN ERTUGLIFLOZIN AND SITAGLIPTIN OR METFORMIN IN HEALTHY SUBJECTS.
    Kumar, V.
    Sahasrabudhe, V.
    Matschke, K.
    Shi, H.
    Alvey, C.
    Fountaine, R. J.
    Hickman, A.
    Saur, D.
    Terra, S. G.
    Zhou, S.
    Krishna, R.
    Cutler, D. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S47 - S47
  • [4] Lack of pharmacokinetic interaction between multiple doses of the dipepttdyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects.
    Karim, A.
    Fleck, P.
    Harris, S.
    Weiss, M.
    Zhang, W.
    Mekki, Q.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S12 - S13
  • [5] LACK OF A CLINICALLY MEANINGFUL PHARMACOKINETIC INTERACTION BETWEEN ERTUGLIFLOZIN AND GLIMEPIRIDE OR SIMVASTATIN IN HEALTHY SUBJECTS.
    Sahasrabudhe, V.
    Kumar, V.
    Matschke, K.
    Shi, H.
    Alvey, C.
    Liang, Y.
    Fountaine, R. J.
    Hickman, A.
    Saur, D.
    Terra, S. G.
    Zhou, S.
    Cutler, D. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S46 - S47
  • [6] Lack of pharmacokinetic interaction between retigabine and phenobarbital at steady-state in healthy subjects.
    Ferron, GM
    Patat, A
    Parks, V
    Rolan, P
    Troy, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P48 - P48
  • [7] No pharmacokinetic interaction between nebivolol and furosemide in healthy subjects.
    Morton, TL
    Liu, S
    Phillips, JL
    Donnelly, CM
    Rackley, RJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P79 - P79
  • [8] Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects.
    Lee, Y
    Orlowski, LH
    Michiels, N
    Petty, KJ
    Goldberg, MR
    Dru, J
    Chavez-Eng, CM
    Constanzer, M
    Murphy, G
    Gottesdiener, K
    Hesney, M
    Feuring, M
    Wehling, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P66 - P66
  • [9] Absence of pharmacokinetic interaction between vildagliptin and digoxin in healthy subjects
    He, Y. L.
    Sabo, R.
    Leon, S.
    Bizot, M. N.
    Riviere, G.
    Sunkara, G.
    Ligueros-Saylan, M.
    Dole, W. P.
    Howard, D.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1082 - 1082
  • [10] No pharmacokinetic interaction between trimethoprim and paliperidone ER in healthy subjects.
    Cleton, A
    Cleton, A
    Talluri, K
    Leempoels, J
    Thyssen, A
    Janssens, L
    Eerdekens, M
    Boom, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P22 - P22
12345